PU
Therapeutic Areas
Cambridge Nucleomics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sepsis Diagnostic | Sepsis (Pathogen ID & AMR Profiling) | Pre-clinical |
| Precision Oncology Liquid Biopsy | Early Cancer Screening & Circulating Tumor Biomarker Detection | Exploratory |
Leadership Team at Cambridge Nucleomics
DH
Dr Hendrik Runge
Founder & CEO
DA
Dr Anthony Cooke
Chairman
JY
John Yeomans
Director
DM
Dr Max Zhu, MBA
Director
DG
Dr Gerardo Patiño Guillén
Nanotechnology Lead
DM
Dr Melanie Stammers
RNA Biology Lead
DR
Dr Rui Abreu Pereira
Microbiology Lead